Annexon also said that a Phase 1 study for its drug ANX1502 supports advancement of the product into a proof-of-concept study ...
In 5 years' time, this author would expect further studies directed at unrevealing the molecular basis of reactive hyperplasia, atypical lymphoid proliferations and lymphomas. There will be more ...
Multiple Value-creating Catalysts Across the Annexon Portfolio Throughout 2024Pivotal Phase 3 Data for ANX005 in Guillain-Barré Syndrome (GBS) ...